Abk Biomedical Inc
Halifax, CA · Founded 2012 · Nova Scotia, Canada corporation · 41 employees on LinkedIn · 3 known investors
Find your way into Abk Biomedical Inc
124 people in our graph share verified history with the Abk Biomedical Inc team — schools, employers, funds. One of them is your warm intro.
Graham Careyunlockedknows Robert Abraham · together at Dalhousie University (overlapped)
×5knows the team · via Dublin City University
knows the team · via Dalhousie University
×4knows the team · via University of Limerick
knows the team · via Royal College of Physicians and Surgeons of Canada
ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.
Founders & leadership
Abk Biomedical Inc was founded in 2012 by Robert Abraham, Daniel Boyd, and Sharon Kehoe.
RA
Robert AbrahaminCo-founder (Interventional Radiologist, MD)Robert Abraham is an interventional radiologist and physician with board certification (FRCPC) and fellowship credentials in interventional radiology (FSIR, FCIRSE). He co-founded ABK Biomedical, a clinical-stage medical device company developing x-ray visible microspheres for radioembolization and cancer treatment, spun out of Dalhousie University.
DB
Daniel BoydinCo-founder (Material Scientist)Daniel Boyd is a material scientist and co-founder of ABK Biomedical, a clinical-stage medical device company developing x-ray visible glass microspheres for Y-90 radioembolization in cancer treatment. With nearly two decades of experience in academic research and product development, he has founded multiple medical device companies and holds numerous patents.
SK
Sharon KehoeinCo-founder (Material Scientist)Sharon Kehoe is a material scientist and co-founder of ABK Biomedical, a clinical-stage medical device company developing x-ray visible glass microspheres for radioembolization and cancer treatment. Her background spans biomaterial formulation, tissue engineering, and biological evaluation of medical materials.
AH
Anthony HeadleyinSVP, Manufacturing, R&D, and Engineering
GD
Gary DonofrioinChief Business Officer
MM
Michael ManganoinPresident and CEO
DD
David DobrowskyExecutive
LB
Lucy BataneantExecutive
MG
Marc GregoireinVice President of R&D and Nuclear Operations
MT
Mike TysoninCFO
DD
David DobrowskiinVice President Clinical Development & Regulatory Affairs
JM
James McLarenNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$80.7M disclosed across 4 rounds · 2019–2025
▶$2.6MraisedNov 2025 · 6 investors · OtherRule 506(b)
▶$2.6MraisedNov 2025 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Lucy BataneantExecutive Officer
- Aravind ArepallyExecutive Officer
- David DobrowskyExecutive Officer
- Joseph SilettoDirector
- James McLarenDirector
- Marc GregoireExecutive Officer
- Aaron BerezDirector
- Keten PatelDirector
- Anthony HeadleyExecutive Officer
- Carissa Bellardine BlackDirector
- Mike TysonExecutive Officer
- James EadieDirector
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$26.1MraisedMay 2025 · 24 investors · OtherRule 506(b)
▶$26.1MraisedMay 2025 · 24 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskyExecutive Officer
- Keten PatelDirector
- Lucy BataneantExecutive Officer
- Joseph SilettoDirector
- Marc GregoireExecutive Officer
- Carissa Bellardine BlackDirector
- Aaron BerezDirector
- James EadieDirector
- Mike TysonExecutive Officer
- James McLarenDirector
- Aravind ArepallyExecutive Officer
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Apr 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$28.5MraisedDec 2022 · 23 investors · OtherRule 506(b)
▶$28.5MraisedDec 2022 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Ketan PatelDirector
- Marc GregoireExecutive Officer
- Aravind ArepallyExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskiExecutive Officer
- Aaron BerezDirector
- James McLarenDirector
- Mike TysonExecutive Officer
- Gary DonofrioExecutive Officer
- Carissa BlackDirector
- Offering amount
- $28.5M
- Amount sold
- $28.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$23.5MraisedApr 2019 · 10 investors · BiotechnologyRule 506(b)
▶$23.5MraisedApr 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McLarenDirector
- Michael TysonExecutive Officer
- David DobrowskiExecutive Officer
- Robert OrrDirector
- Aaron BerezDirector
- Bob AbrahamExecutive Officer, Director
- Marc GregoireExecutive Officer
- Michael ManganoExecutive Officer, Director
- Gary DonofrioExecutive Officer
- Offering amount
- $23.5M
- Amount sold
- $23.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
IQVIA8 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Topera7 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Companies competing with Abk Biomedical Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Abk Biomedical Inc do?
- ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.
- Who founded Abk Biomedical Inc?
- Abk Biomedical Inc was founded by Robert Abraham, Daniel Boyd, Sharon Kehoe in 2012.
- Who are Abk Biomedical Inc's investors?
- Abk Biomedical Inc's investors include Eight Roads Ventures, F-Prime Capital, Vivo Capital.
- How much funding has Abk Biomedical Inc raised?
- Abk Biomedical Inc has disclosed $80.7M raised across 4 rounds.
- Where is Abk Biomedical Inc headquartered?
- Abk Biomedical Inc is headquartered in Halifax, CA.